Overview

Safety and Efficacy Evaluation of Decitabine With R-GDP

Status:
Unknown status
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
Assessment of the Safety and efficacy of Administering decitabin plus R-GDP to NHL patients
Phase:
Phase 1
Details
Lead Sponsor:
Beijing Immunochina Medical Science & Technology Co., Ltd.
Treatments:
Azacitidine
Decitabine